The risk of infection associated with tumor necrosis factor antagonists (anti-TNF) and thiopurines (combination therapy) is uncertain. We assessed the risk of serious and opportunistic infections in patients with IBD treated with thiopurine monotherapy, anti-TNF monotherapy, or combination therapy in a large cohort of patients in France.